Iloperidone (Fanapt) vs Risperidone (Risperdal Consta)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (Fanapt)
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Reported efficacy
Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)
Result source: NCT00254202
Risperidone (Risperdal Consta)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo.
Reported efficacy
Change from baseline to the end of double-blind treatment in the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) total score: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly. (met)
Result source: NCT00253136
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Iloperidone (Fanapt) | Risperidone (Risperdal Consta) |
|---|---|---|
| PANSS total, change | -12 vs -7.1−4.9 vs placeboNCT002542021 other result
| -9.3 vs -1.1vs QuetiapineNCT002164761 other result
|
| CGI-S, change | —Trial running · NCT06961968 | -0.3 vs 0.1vs QuetiapineNCT002164761 other result
|
| PANSS response | —Trial running · NCT06961968 | —Not posted · NCT00216580 |
| PSP, change | —Trial running · NCT06961968 | 5.3 vs 6.0vs Risperidone TabletsNCT00992407 |
| Relapse (% of patients) | —Trial running · NCT06961968 | 5% vs 32.6%vs RisperidoneNCT003305511 other result
|
PANSS total, change
- Iloperidone (Fanapt)
- -12 vs -7.1−4.9 vs placeboNCT00254202
1 other result
- 1.1 vs 12.4 NCT01291511
- Risperidone (Risperdal Consta)
- -9.3 vs -1.1vs QuetiapineNCT00216476
1 other result
- -11.7 vs -13 NCT00992407
CGI-S, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal Consta)
- -0.3 vs 0.1vs QuetiapineNCT00216476
1 other result
- -0.6 vs -0.7 NCT00992407
PANSS response
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal Consta)
- —Not posted · NCT00216580
PSP, change
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal Consta)
- 5.3 vs 6.0vs Risperidone TabletsNCT00992407
Relapse (% of patients)
- Iloperidone (Fanapt)
- —Trial running · NCT06961968
- Risperidone (Risperdal Consta)
- 5% vs 32.6%vs RisperidoneNCT00330551
1 other result
- 34.4% vs 16.1% NCT00246259
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Iloperidone (Fanapt): 5 of 5 rows · Risperidone (Risperdal Consta): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Iloperidone (Fanapt) | Risperidone (Risperdal Consta) Rows use multiple source trials |
|---|---|---|
| Time to Relapse time to event · months | NA vs 3.25 placebo months @ 26wka,b,c,d NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 | 18.58 vs 18.35 Oral Antipsychotic months*a,b,c,d NCT00246259 · Phase 4 · registry result, not featured evidence · converted to months from 80.5 weeks as posted |
| Dropout rate | 34.6%e NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results51.3%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 30.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 31.5%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence 18.8%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 12.5%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 13.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 6.7%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 38.4%f NCT00132314 · Phase 3 show 14 more results5.9%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 14.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 5.9%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 25%Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence —Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 29.5% NCT00539071 · Phase 4 · registry result, not featured evidence 83.8% NCT00992407 · Phase 4 · registry result, not featured evidence 26.5% NCT00130923 · Phase 4 · registry result, not featured evidence 31.8% NCT00216671 · Phase 4 · registry result, not featured evidence 63.6% NCT00246259 · Phase 4 · registry result, not featured evidence 67.5% NCT00269919 · Phase 4 · registry result, not featured evidence 45.3% NCT01726335 · Phase 4 · registry result, not featured evidence 31.9% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —e NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results14.5%Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 —Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 10.4%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 15%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | —f NCT00132314 · Phase 3 show 14 more results—CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence —Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence — NCT00539071 · Phase 4 · registry result, not featured evidence 18.9% NCT00992407 · Phase 4 · registry result, not featured evidence — NCT00130923 · Phase 4 · registry result, not featured evidence 5.5% NCT00216671 · Phase 4 · registry result, not featured evidence 11.4% NCT00246259 · Phase 4 · registry result, not featured evidence — NCT00269919 · Phase 4 · registry result, not featured evidence 7.5% NCT01726335 · Phase 4 · registry result, not featured evidence 1.8% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0.7%e NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 24 more results—Iloperidone NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone (Cross-titration and S NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 4%Iloperidone (Relapse-prevention Ph NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 3.3%Iloperidone Gradual Switch NCT01207414 · Phase 4 · registry result, not featured evidence 2.7%Iloperidone Immediate Switch NCT01207414 · Phase 4 · registry result, not featured evidence —625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%625 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%500 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 14.3%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 7.1%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence —250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%250 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%125 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence 0%50 mg NCT01348100 · Phase 1/2 · registry result, not featured evidence | 51.3%f NCT00132314 · Phase 3 show 14 more results18.8%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 5%Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 6.4% NCT00539071 · Phase 4 · registry result, not featured evidence 0% NCT00992407 · Phase 4 · registry result, not featured evidence 32.7% NCT00130923 · Phase 4 · registry result, not featured evidence 16.4% NCT00216671 · Phase 4 · registry result, not featured evidence 4.5% NCT00246259 · Phase 4 · registry result, not featured evidence 15.4% NCT00269919 · Phase 4 · registry result, not featured evidence 5.7% NCT01726335 · Phase 4 · registry result, not featured evidence 19.1% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | e headache 20.3% (placebo 19.7%) dizziness 17% (placebo 7.5%) sedation 12.7% (placebo 8.2%) NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 18 more resultsdizziness 11.6% (placebo 2.7%) somnolence 8.3% (placebo 0%) dry mouth 6.8% (placebo 0%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dizziness 2.6% (placebo 2.7%) headache 2% (placebo 3.3%) insomnia 2% (placebo 4.7%) NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3 dry mouth 17.9% dizziness 17.5% somnolence 14.2% NCT01207414 · Phase 4 · registry result, not featured evidence dizziness 22.3% dry mouth 20.8% insomnia 9.6% NCT01207414 · Phase 4 · registry result, not featured evidence 625 mg injection site pain 66.7% injection site induration 60% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 625 mg headache 20% nasal congestion 20% anxiety 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg injection site pain 60% injection site induration 26.7% injection site swelling 20% NCT01348100 · Phase 1/2 · registry result, not featured evidence 500 mg nasal congestion 33.3% constipation 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg back pain 7.1% constipation 7.1% headache 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg insomnia 20% headache 13.3% somnolence 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg constipation 14.3% headache 14.3% anxiety 7.1% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg headache 33.3% insomnia 33.3% dyspepsia 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg injection site pain 53.3% headache 26.7% nasal congestion 26.7% NCT01348100 · Phase 1/2 · registry result, not featured evidence 250 mg nasal congestion 40% headache 26.7% oropharyngeal pain 13.3% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg pruritus 50% throat irritation 50% upper respiratory tract infection 50% NCT01348100 · Phase 1/2 · registry result, not featured evidence 125 mg constipation 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg blood creatine phosphokinase increased 50% agitation 0% akathisia 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence 50 mg dizziness 50% headache 50% agitation 0% NCT01348100 · Phase 1/2 · registry result, not featured evidence | show 13 more resultsbmi increase normal/overweight to obese 31.3% ldl or triglyceride increase 25% prolactin related symptom 12.5% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 25% prolactin related symptom 16.7% ldl or triglyceride increase 8.3% NCT00333177 · Phase 4 · registry result, not featured evidence ldl or triglyceride increase 41.7% prolactin related symptom 16.7% bmi increase normal/overweight to obese 0% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 12.5% ldl or triglyceride increase 6.3% prolactin related symptom 6.3% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase from normal or overweight to obese 17.5% prolactin related 7.5% lipid increase 5% NCT00330551 · Phase 4 · registry result, not featured evidence non-serious adverse events 16.7% NCT00539071 · Phase 4 · registry result, not featured evidence akathisisa 10% anxiety 10% muscle rigidity 10% NCT00992407 · Phase 4 · registry result, not featured evidence insomnia 10.2% pain 10.2% vomiting 10.2% NCT00130923 · Phase 4 · registry result, not featured evidence insomnia 8.2% akathisia 7.3% weight increased 7.3% NCT00216671 · Phase 4 · registry result, not featured evidence headache 34.1% insomnia 29.5% fatigue 25% NCT00246259 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 20.5% akathisia 12.8% vision blurred 10.3% NCT00269919 · Phase 4 · registry result, not featured evidence libido decreased 22.6% weight increased 13.2% blood prolactin increased 11.3% NCT01726335 · Phase 4 · registry result, not featured evidence hyperprolactinaemia 13.1% anxiety 11.9% insomnia 10.9% NCT00216476 · Phase 3 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for 21 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Iloperidone (Fanapt)
show 1 more result
show 3 more results
Risperidone (Risperdal Consta)
show 3 more results
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 7 more results
+ 31 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Risperidone (Risperdal Consta)'s landscape